Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition

Alzheimer's Research and Therapy

Volumn 6, Issue 1, 2014, Pages

  Selenica, Maj Linda ^a,b   Benner, Leif ^a   Housley, Steven B ^a   Manchec, Barbara ^a   Lee, Daniel C ^a,b   Nash, Kevin R ^a,c   Kalin, Jay ^d   Bergman, Joel A ^e   Kozikowski, Alan ^e   Gordon, Marcia N ^a,c   Morgan, Dave ^a,c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; TAU PROTEIN; TUBASTATIN A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ATROPHY; CONTROLLED STUDY; HIPPOCAMPUS; HYPERACTIVITY; MEMORY DISORDER; MOUSE; MOUSE MODEL; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN PHOSPHORYLATION; SPATIAL ORIENTATION; TAUOPATHY;

EID: 84989182910     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt241     Document Type: Article

References (47)

1. Boeve BF, Hutton M: Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP-17 (MAPT) and FTDP-17 (PGRN). Arch Neurol 2008, 65:460-464.
2. Himmelstein DS, Ward SM, Lancia JK, Patterson KR, Binder LI: Tau as a therapeutic target in neurodegenerative disease. Pharmacol Ther 2012, 136:8-22.
3. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kovari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, et al: Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol 2012, 71:362-381.
4. Hoshino I, Matsubara H: Recent advances in histone deacetylase targeted cancer therapy. Surg Today 2010, 40:809-815.
5. Dallavalle S, Pisano C, Zunino F: Development and therapeutic impact of HDAC6-selective inhibitors. Biochem Pharmacol 2012, 84:756-765.
6. Butler KV, Kalin J, Brochier C, Vistoli G, Langley B, Kozikowski AP: Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc 2010, 132:10842-10846.
7. d'ydewalle C, Van Den Bosch L, Robberecht W, Timmerman V, Vanden Berghe P, Kozikowski AP, Irobi J, Van Damme P, Chiheb DM, Krishnan J: HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat Med 2011, 17:968-974.
8. Cook C, Gendron TF, Scheffel K, Carlomagno Y, Dunmore J, DeTure M, Petrucelli L: Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation. Hum Mol Genet 2012, 21:2936-2945.
9. Xiong Y, Zhao K, Wu J, Xu Z, Jin S, Zhang YQ: HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila. Proc Natl Acad Sci U S A 2013, 110:4604-4609.
10. Mandelkow EM, Mandelkow E: Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harbor Perspect Med 2012, 2:a006247.
11. Morris JC, Price AL: Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 2001, 17:101-118.
12. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH: Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309:476-481.
13. Gordon MN, King DL, Diamond DM, Jantzen PT, Boyett KL, Hope CE, Hatcher JM, DiCarlo G, Gottschal P, Morgan D, Arendash GW: Correlation between cognitive deficits and Aá deposits in transgenic APP + PS1 mice. Neurobiol Aging 2001, 22:377-385.
14. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW: A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
15. Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D: Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Gen 1999, 29:177-185.
16. Holcomb LA, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K: Accelerated Alzheimer-Type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998, 4:97-100.
17. Morgan D, Holcomb L, Saad I, Gordon M, Mahin M: Impaired spatial navigation learning in transgenic mice over-expressing heme oxygenase-1. Brain Res 1998, 808:110-112.
18. Anisman H: Time-dependent variations in aversively motivated behaviors: nonassociative effects of cholinergic and catecholaminergic activity. Psychol Rev 1975, 82:359-385.
19. Alamed J, Wilcock DM, Diamond DM, Gordon MN, Morgan D: Two-day radial-Arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat Protoc 2006, 1:1671-1679.
20. Garcia MF, Gordon MN, Hutton M, Lewis J, McGowan E, Dickey CA, Morgan D, Arendash GW: The retinal degeneration (rd) gene seriously impairs spatial cognitive performance in normal and Alzheimer's transgenic mice. NeuroReport 2004, 15:73-77.
21. Planel E, Richter KE, Nolan CE, Finley JE, Liu L, Wen Y, Krishnamurthy P, Herman M, Wang L, Schachter JB, Nelson RB, Lau LF, Duff KE: Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J Neurosci 2007, 27:3090-3097.
22. Selenica ML, Alvarez JA, Nash KR, Lee DC, Cao C, Lin X, Reid P, Mouton PR, Morgan D, Gordon MN: Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain. J Neuroinflammation 2013, 10:86.
23. Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, Johnson A, Blair L, Gordon MN, Dickey CA, Morgan D: LPS-induced inflammation exacerbates phospho-Tau pathology in rTg4510 mice. J Neuroinflamm 2010, 7:56.
24. Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, Melachrino J, O'Callaghan JP, Morgan D: Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1 + APP mouse. Exp Neurol 2002, 173:183-195.
25. Carroll JC, Iba M, Bangasser DA, Valentino RJ, James MJ, Brunden KR, Lee VM, Trojanowski JQ: Chronic stress exacerbates tau pathology, neurodegeneration, and cognitive performance through a corticotropin-releasing factor receptor-dependent mechanism in a transgenic mouse model of tauopathy. J Neurosci 2011, 31:14436-14449.
26. Courchesne E, Mouton PR, Calhoun ME, Semendeferi K, Ahrens-Barbeau C, Hallet MJ, Barnes CC, Pierce K: Neuron number and size in prefrontal cortex of children with autism. JAMA 2011, 306:2001-2010.
27. Govindarajan N, Rao P, Burkhardt S, Sananbenesi F, Schluter OM, Bradke F, Lu J, Fischer A: Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease. EMBO Mol Med 2013, 5:52-63.
28. O'Leary JC 3rd, Li Q, Marinec P, Blair LJ, Congdon EE, Johnson AG, Jinwal UK, Koren J 3rd, Jones JR, Kraft C, Peters M, Abisambra JF, Duff KE, Weeber EJ, Gestwicki JE, Dickey CA: Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol Neurodegener 2010, 5:45.
29. Dickey C, Kraft C, Jinwal U, Koren J, Johnson A, Anderson L, Lebson L, Lee D, Dickson D, de Silva R, Binder LI, Morgan D, Lewis J: Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy. Am J Pathol 2009, 174:228-238.
30. Graff J, Tsai LH: Histone acetylation: molecular mnemonics on the chromatin. Nat Rev Neurosci 2013, 14:97-111.
31. Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai LH: Recovery of learning and memory is associated with chromatin remodelling. Nature 2007, 447:178-182.
32. Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, Nieland TJ, Zhou Y, Wang X, Mazitschek R, Bradner JE, DePinho RA, Jaenisch R, Tsai LH: HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009, 459:55-60.
33. Graff J, Rei D, Guan JS, Wang WY, Seo J, Hennig KM, Nieland TJ, Fass DM, Kao PF, Kahn M, Su SC, Samiei A, Joseph N, Haggarty SJ, Delalle I, Tsai LH: An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 2012, 483:222-226.
34. Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, Sweatt JD, Rumbaugh G: Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 2010, 35:870-880.
35. Francis YI, Fa M, Ashraf H, Zhang H, Staniszewski A, Latchman DS, Arancio O: Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. J Alzheimers Dis 2009, 18:131-139.
36. Ricobaraza A, Cuadrado-Tejedor M, Perez-Mediavilla A, Frechilla D, Del Rio J, Garcia-Osta A: Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology 2009, 34:1721-1732.
37. Ricobaraza A, Cuadrado-Tejedor M, Garcia-Osta A: Long-Term phenylbutyrate administration prevents memory deficits in Tg2576 mice by decreasing Aβ. Front Biosci (Elite Ed) 2011, 3:1375-1384.
38. de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT: Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 2012, 73:685-697.
39. Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K: Trans-synaptic spread of tau pathology in vivo. PLoS One 2012, 7:e31302.
40. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP: HDAC6 is a microtubule-Associated deacetylase. Nature 2002, 417:455-458.
41. Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D, Osada H, Komatsu Y, Nishino N, Khochbin S, Horinouchi S, Yoshida M: In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J 2002, 21:6820-6831.
42. Kim C, Choi H, Jung ES, Lee W, Oh S, Jeon NL, Mook-Jung I: HDAC6 inhibitor blocks amyloid beta-induced impairment of mitochondrial transport in hippocampal neurons. PLoS One 2012, 7:e42983.
43. Asthana J, Kapoor S, Mohan R, Panda D: Inhibition of HDAC6 deacetylase activity increases its binding with microtubules and suppresses microtubule dynamic instability in MCF-7 cells. J Biol Chem 2013, 288:22516-22526.
44. Ding H, Dolan PJ, Johnson GV: Histone deacetylase 6 interacts with the microtubule-Associated protein tau. J Neurochem 2008, 106:2119-2130.
45. Perez M, Santa-Maria I, Gomez de Barreda E, Zhu X, Cuadros R, Cabrero JR, Sanchez-Madrid F, Dawson HN, Vitek MP, Perry G, Smith MA, Avila J: Tau-An inhibitor of deacetylase HDAC6 function. J Neurochem 2009, 109:1756-1766.
46. Simoes-Pires C, Zwick V, Nurisso A, Schenker E, Carrupt PA, Cuendet M: HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs? Mol Neurodegener 2013, 8:7.
47. Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.